SPON2 acts as a tumor promoter in HR-positive/HER2-negative breast cancer by regulating β-catenin signaling
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2025.07.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Gu-Yue Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shanghai Putuo People's Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: guyue065…. Hauptthemen laut MEDLINE: Breast Neoplasms, beta Catenin, Extracellular Matrix Proteins. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Shanghai Putuo People's Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: guyue0652@hhu.edu.cn.
- Department of General Surgery, Shanghai Putuo People's Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of General Surgery, Shanghai Putuo People's Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: 18721033022@163.com.
Zitieren
APA
Liu, G. Y., Huang, D. P., Ge, C., Li, X. Y., Chen, F., Fan, J. S., & Tu, H. P. (2026). SPON2 acts as a tumor promoter in HR-positive/HER2-negative breast cancer by regulating β-catenin signaling. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.07.030
Vancouver
Liu GY, Huang DP, Ge C, Li XY, Chen F, Fan JS, et al. SPON2 acts as a tumor promoter in HR-positive/HER2-negative breast cancer by regulating β-catenin signaling. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2025.07.030
BibTeX
@article{Liu2026,
author = {Liu, Gu-Yue and Huang, Dong-Ping and Ge, Can and Li, Xiao-Yu and Chen, Fei and Fan, Jia-Shu and Tu, Huan-Ping},
title = {SPON2 acts as a tumor promoter in HR-positive/HER2-negative breast cancer by regulating β-catenin signaling},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2025.07.030}
}
EUVIMED